INHIBRX BIOSCIENCES, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
INHIBRX BIOSCIENCES, INC. (INBX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$140.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-19
- INHIBRX BIOSCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$140.05M, a 108.30% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $1.69B.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$140.05M 10-K · filed 2026-03-19 |
| 2024-12-31 | $1.69B 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |